SCHEMBL990285

SCHEMBL990285

CC(C)Cc1nc2ccc(-c3c(-c4ccccc4)ncn3C3CCCCC3)cc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
MAPT P10636 1/20 0.41
MAPK14 Q16539 5/20 0.40
EGFR P00533 3/20 0.38
MAPK13 O15264 2/20 0.38
MAPK12 P53778 2/20 0.38
MAPK11 Q15759 2/20 0.38
CSNK1D P48730 1/20 0.38
CSNK1E P49674 1/20 0.38
KCNH2 Q12809 1/20 0.38
AAK1 Q2M2I8 4/20 0.38
TNIK Q9UKE5 1/20 0.37
LDHA P00338 1/20 0.37
PDE10A Q9Y233 1/20 0.37
PRKCZ Q05513 1/20 0.36
ACVR1 Q04771 1/20 0.36
IGF1R P08069 2/20 0.35
ERBB2 P04626 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL990284 0.76 MAPK14 (0.47) KDM4EMAPK14EGFRMAPK13MAPK12
SCHEMBL990252 0.76 SPHK1 (0.45) MAPK14EGFRMAPK13MAPK12MAPK11
SCHEMBL991427 0.75 MAPK14 (0.50) MAPK14EGFRMAPK13MAPK12MAPK11
SCHEMBL4837487 0.74 MAPK14 (0.41) MAPK14EGFRMAPK13MAPK12MAPK11
SCHEMBL989412 0.72 MAPK14 (0.41) KDM4EMAPK14EGFRMAPK13MAPK12
SCHEMBL4837575 0.71 MAPK14 (0.72) MAPK14EGFRCSNK1DERBB2
SCHEMBL4834028 0.71 PIK3CA (0.52) KDM4EMAPTMAPK14EGFRMAPK13
SCHEMBL4838938 0.71 MAPK14 (0.41) MAPK14EGFRMAPK13MAPK12MAPK11
SCHEMBL4837492 0.69 MAPK14 (0.41) MAPK14EGFRMAPK13MAPK12MAPK11
SCHEMBL991479 0.69 MAPT (0.46) MAPTMAPK14EGFRMAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863310-B2 Kinase inhibitors ELI LILLY AND COMPANY (US) 2011-01-04 US disclosed
US-20080227839-A1 Kinase Inhibitors ELI LILLY AND COMPANY 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227839-A1 Kinase Inhibitors ABL1, MAP3K20, MAP3K19 KDM4E 900/4885MAPT 2603/4885MAPK14 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.